MIRUM PHARMACEUTICALS INC
NASDAQ: MIRM (Mirum Pharmaceuticals, Inc.)
Last update: 1 hour ago69.16
-1.28 (-1.81%)
| Previous Close | 70.44 |
| Open | 70.87 |
| Volume | 395,858 |
| Avg. Volume (3M) | 701,798 |
| Market Cap | 3,554,380,032 |
| Price / Earnings (Forward) | 833.33 |
| Price / Sales | 7.47 |
| Price / Book | 12.57 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | -20.39% |
| Operating Margin (TTM) | -13.61% |
| Diluted EPS (TTM) | -1.61 |
| Quarterly Revenue Growth (YOY) | 61.20% |
| Total Debt/Equity (MRQ) | 135.97% |
| Current Ratio (MRQ) | 3.22 |
| Operating Cash Flow (TTM) | -6.85 M |
| Levered Free Cash Flow (TTM) | -23.97 M |
| Return on Assets (TTM) | -7.11% |
| Return on Equity (TTM) | -33.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Mirum Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 1.00 |
|
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter “IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.90% |
| % Held by Institutions | 114.19% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 30 Sep 2025 | 6,795,121 |
| Eventide Asset Management, Llc | 30 Sep 2025 | 2,522,563 |
| Novo Holdings A/S | 30 Sep 2025 | 1,264,028 |
| Tang Capital Management Llc | 30 Sep 2025 | 1,236,027 |
| Clearbridge Investments, Llc | 30 Sep 2025 | 1,003,803 |
| D. E. Shaw & Co., Inc. | 30 Sep 2025 | 923,509 |
| Polar Capital Holdings Plc | 30 Sep 2025 | 820,552 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 95.00 (Cantor Fitzgerald, 37.36%) | Buy |
| 95.00 (Citizens, 37.36%) | Buy | |
| 95.00 (TD Cowen, 37.36%) | Buy | |
| Median | 88.00 (27.24%) | |
| Low | 77.00 (JP Morgan, 11.34%) | Buy |
| Average | 87.33 (26.27%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 72.21 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 05 Nov 2025 | 95.00 (37.36%) | Buy | 70.09 |
| Citizens | 05 Nov 2025 | 95.00 (37.36%) | Buy | 70.09 |
| HC Wainwright & Co. | 05 Nov 2025 | 81.00 (17.12%) | Buy | 70.09 |
| Morgan Stanley | 16 Oct 2025 | 81.00 (17.12%) | Buy | 74.42 |
| TD Cowen | 24 Sep 2025 | 95.00 (37.36%) | Buy | 74.26 |
| JP Morgan | 12 Sep 2025 | 77.00 (11.34%) | Buy | 74.31 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |